By Julia Karow

2010 might well become known as the dawn of the Cambrian period for next-gen sequencing, as the number of sequencing platforms mushroomed during the year, a trend that's likely to continue.

As new sequencers catering to different types of users appeared on the market, the two biggest players in the industry — Illumina and Life Technologies — continued to battle each other with promises of more DNA bases at lower cost with greater accuracy and speed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.